 Subjects will be randomized to 2 arms, in a 1:1 ratio, to a DCS medication group n20 and a placebo medication group n20. Questionnaire outcomes and brain scans will occur prior to initiating treatment and at the end of the treatment period. The actual visits required are minimized, 9 visits spread out over 21 weeks, as pain, quality of life and pill ingestion timings are collected using a secure study website accessible electronically. 